Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Felix Feng, MD, University of California San Francisco, San Francisco, CA, discusses the validation of a prognostic genomic classifier for salvage radiotherapy prostate cancer (PC) patients from the RTOG 9601 trial who had PSA recurrences after prostatectomy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.